Posted On: 09/16/2016 9:23:36 AM
Post# of 18309
$RGBP SAN DIEGO, California, September 14, 2016 /PRNewswire/ --
Regen BioPharma, Inc. (RGBP), (RGBPP), announced today submission to the Food and Drug Administration (FDA) of a revised Investigational New Drug (IND) application focused on using a novel method to unleash the body's innate ability to kill cancer. The package submitted contained preclinical experiments as well as details of the proposed clinical trial. Results of the studies clearly demonstrated that the approach outlined, using siRNA to silence a key enzyme related to inhibition of the immune system, is effective at stimulating the type of immune response associated with known checkpoint inhibitors.
https://finance.yahoo.com/news/regen-biopharm...00789.html
Regen BioPharma, Inc. (RGBP), (RGBPP), announced today submission to the Food and Drug Administration (FDA) of a revised Investigational New Drug (IND) application focused on using a novel method to unleash the body's innate ability to kill cancer. The package submitted contained preclinical experiments as well as details of the proposed clinical trial. Results of the studies clearly demonstrated that the approach outlined, using siRNA to silence a key enzyme related to inhibition of the immune system, is effective at stimulating the type of immune response associated with known checkpoint inhibitors.
https://finance.yahoo.com/news/regen-biopharm...00789.html
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼
